title: Hydroxypropylated tapioca starch retards the development of insulin resistance in KKAy mice, a type 2 diabetes model, fed a high-fat diet.
abstract: The hypoglycemic and antidiabetic effect of hydroxypropyl tapioca starch (HPTS, degree of substitution = 0.180) was investigated in male KKAy mice. Mice were fed a purified high-fat (20%) diet without or with HPTS (5% or 10%) for 33 d. Gelatinized tapioca starch (TS) was used as a reference. Fasting blood glucose concentrations, days 14 and 28, were significantly lower in the 10% HPTS group compared with the reference. In an oral glucose tolerance test (OGTT), day 28, blood glucose concentrations in the 5% HPTS group, at 60, 90, and 120 min, and in the 10% HPTS group, at 30, 60, and 90 min after oral administration of glucose, were significantly lower compared with the reference. The area under the glucose curve (AUC) for glucose in both HPTS groups was significantly lower compared with the reference. Energy intake was significantly lower in the 10% HPTS group compared with the reference. At the end of the experiment, adiponectin concentrations were significantly higher in the 10% HPTS group compared with the reference. A homeostasis model assessment of insulin resistance (HOMA-IR) tended to be lower in the 10% HPTS group compared with the reference, whereas a quantitative insulin sensitivity check index (QUICKI) was significantly higher in both HPTS groups compared with the reference. These results show that HPTS retards the development of insulin resistance in KKAy mice fed a high-fat diet.
authors.affiliation: Matsutani Chemical Industry Co., Ltd., Research Laboratory, 5-3 Kitaitami, Itami 664-8508, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Tachibe
authors.forename: Ryo
authors.initials: R
authors.lastname: Kato
authors.forename: Shozo
authors.initials: S
authors.lastname: Sugano
authors.forename: Taro
authors.initials: T
authors.lastname: Kishida
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ebihara
mesh_terms: D017667:Adipocytes / Q000473:pathology; D052242:Adiponectin / Q000097:blood; D050154:Adiposity; D000818:Animals; D048429:Cell Size; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D004041:Dietary Fats / Q000008:administration & dosage*; D002149:Energy Intake; D004852:Epoxy Compounds / Q000737:chemistry; D005951:Glucose Tolerance Test; D006706:Homeostasis; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D002365:Manihot / Q000737:chemistry*; D051379:Mice; D013213:Starch / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D015430:Weight Gain
chemical_list: D052242:Adiponectin; D004041:Dietary Fats; D004852:Epoxy Compounds; D007004:Hypoglycemic Agents; D013213:Starch; C009068:propylene oxide